Sun Pharmaceutical Industries reported its September quarter results on 2 November 2026. Consolidated revenue rose 11.8% year on year to Rs 16,100 crore, and adjusted net profit came in at Rs 3,162 crore. Sales in India grew 17.3% to Rs 5,552 crore, and the company’s share of the Indian drug market rose to 8.6%, according to Pharmarack data quoted with the results. Innovative medicines, the patented specialty drugs Sun has spent a decade building, brought in $356 million in the quarter.
Those are big numbers for a company that started in 1983 with five psychiatry products and a two-person marketing team. The man behind it, Dilip Shanghvi, is now Executive Chairman. This is how he got here.
The early years
Shanghvi was born on 1 October 1955 in Amreli, Gujarat, and grew up in Kolkata, where his family moved. His father ran a small wholesale business trading generic medicines. Shanghvi studied commerce at the University of Calcutta and worked in the family trade.
That work taught him how medicines actually moved from maker to chemist, and what doctors asked for. According to a 2019 Business Today review of Soma Das’s biography of him, the family shop was the sole Calcutta stockist for Torrent, then the only Indian drug company focused on psychiatry.
The idea
In the late 1970s Shanghvi decided he would rather make medicines than sell other people’s. He started with one psychiatric drug sourced from a local manufacturer and slowly added more in the same specialty. With few Indian companies focused on psychiatry at the time, it was a field where a newcomer could get known.
Sun Pharmaceutical Industries was set up in 1983 with a small loan from his father. The company’s own milestones page says it began with five psychiatry products, a two-person marketing team and a tablet and capsule plant in Vapi, Gujarat. Its first cardiology products, Monotrate and Angize, followed in 1988, and it opened its first research centre in 1991.
The hard part
Shanghvi’s growth plan rested on buying companies that others did not want. Business Today notes that Sun’s three biggest deals, Caraco in the US, Taro in Israel and Ranbaxy in India, were all distressed assets when Sun took them over. Fixing such businesses takes years and ties up cash and management attention.
Ranbaxy was the biggest test. Sun agreed to buy its domestic rival in 2014 in a deal the company puts at about $4 billion. India’s Competition Commission cleared it only after Sun agreed to sell off seven products. The merger made Sun India’s largest drug maker and, by sales, one of the world’s biggest specialty generic companies.
How it grew
Sun listed on the stock market in 1994. In 1997 it made its first overseas purchase, Caraco Pharmaceutical Laboratories in Detroit. It took a controlling stake in Taro in 2010 and bought out the remaining shares in 2024.
The specialty bet started paying off later. In 2014 Sun licensed tildrakizumab from Merck & Co, and the drug launched in the US as Ilumya in 2018 for plaque psoriasis. Odomzo, Cequa and Winlevi followed. In March 2025 Sun bought Checkpoint Therapeutics, a US cancer drug company, for $355 million, and it launched Leqselvi for severe alopecia areata in the US the same year.
In April 2026 came its largest deal yet: an all-cash agreement to buy US drug maker Organon, the women’s health and biosimilars company spun off from Merck in 2021. Reports put the enterprise value at $11.75 billion. Organon shareholders approved the merger in July 2026, and Sun has said it hopes to close the transaction by early 2027, subject to regulatory approvals.
Where it stands now
Sun sells in more than 100 countries and makes medicines at over 40 sites. In September 2025 Kirti Ganorkar, a chemical engineer who joined Sun in 1996 and had run the India business since 2019, took over as Managing Director. Shanghvi stayed on as Executive Chairman to focus on the specialty portfolio and long-term strategy. Announcing the change in June 2025, he said Ganorkar “has consistently demonstrated effective leadership, managing diverse roles at Sun.”
For the first half of FY27, Sun reported sales of Rs 31,284 crore, with innovative medicines making up 21.5% of the total. R&D spending for the half was Rs 1,605 crore, about 5.1% of sales.
Lessons for founders
- Start narrow. Five psychiatry drugs gave a small company a field where it could be known by name.
- Know the trade from the inside. Years in distribution showed Shanghvi what doctors and chemists wanted before he made a single tablet.
- Buy what you can fix. Troubled assets came cheaper, but only because Sun was willing to do the slow work of repairing them.
- Change the model before you have to. The move into specialty drugs began long before it showed up in the numbers.
- Build the next leader from within. Sun’s new MD has spent nearly three decades at the company.
Reporting based on Indian Pharma Post, Sun Pharma milestones, Outlook Business (leadership change), Outlook Business (Organon deal), Business Today and Wikipedia.
Featured image: Raman Patel, via Wikimedia Commons (CC BY 3.0)

